Видео ютуба по тегу Asco Gu

Обзор и обновление Napa 2025: новости по раку мочеполовых органов от ASCO GU — д-р Дивья Парих
Обзор и обновление Napa 2025: новости по раку мочеполовых органов от ASCO GU — д-р Дивья Парих
Highlights in GU cancer at ASCO 2025
Highlights in GU cancer at ASCO 2025
ARASENS Subgroup Analysis & Key ASCO GU 2025 Updates in Prostate Cancer Research
ARASENS Subgroup Analysis & Key ASCO GU 2025 Updates in Prostate Cancer Research
ASCO GU 2025: Neoadjuvant Durvalumab + Chemo in High-Risk Upper Tract Urothelial Carcinoma
ASCO GU 2025: Neoadjuvant Durvalumab + Chemo in High-Risk Upper Tract Urothelial Carcinoma
ASCO GU 2025: CALYPSO Trial – Final OS & ctDNA Analysis in MET-Driven Papillary Renal Cancer
ASCO GU 2025: CALYPSO Trial – Final OS & ctDNA Analysis in MET-Driven Papillary Renal Cancer
ASCO GU 2025: SABR with TKI & IO Therapy in Metastatic Renal Cell Carcinoma – Efficacy & Safety
ASCO GU 2025: SABR with TKI & IO Therapy in Metastatic Renal Cell Carcinoma – Efficacy & Safety
ASCO GU 2025: GROUQ-PCS9 Trial – Metastases-Directed Therapy in Oligometastatic mCRPC
ASCO GU 2025: GROUQ-PCS9 Trial – Metastases-Directed Therapy in Oligometastatic mCRPC
ASCO GU 2025: Exercise Program to Reduce Fatigue in Advanced Prostate Cancer on ADT
ASCO GU 2025: Exercise Program to Reduce Fatigue in Advanced Prostate Cancer on ADT
ASCO GU 2025: Extended Interval Dosing of Denosumab in Metastatic Prostate Cancer Patients
ASCO GU 2025: Extended Interval Dosing of Denosumab in Metastatic Prostate Cancer Patients
ASCO GU 2025: Docetaxel Rechallenge vs Cabazitaxel in Previously Treated mCRPC Patients
ASCO GU 2025: Docetaxel Rechallenge vs Cabazitaxel in Previously Treated mCRPC Patients
ASCO GU 2025: STOPCAP Meta-Analysis on AR Pathway Inhibitors in mHSPC Patients
ASCO GU 2025: STOPCAP Meta-Analysis on AR Pathway Inhibitors in mHSPC Patients
ASCO-GU 2025: Radical Prostatectomy vs Radiotherapy in High-Risk Prostate Cancer (IPD Study)
ASCO-GU 2025: Radical Prostatectomy vs Radiotherapy in High-Risk Prostate Cancer (IPD Study)
Prostate Cancer Breakthroughs: Updates from the 2025 ASCO Annual Meeting | ZERO Prostate Cancer
Prostate Cancer Breakthroughs: Updates from the 2025 ASCO Annual Meeting | ZERO Prostate Cancer
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA
Innovations in GU Cancer Treatment at ASCO25
Innovations in GU Cancer Treatment at ASCO25
Can AI help physicians better understand prostate cancer? 🤖
Can AI help physicians better understand prostate cancer? 🤖
Episode 24: ASCO Annual Meeting 2025 Commentary: Prostate Cancer
Episode 24: ASCO Annual Meeting 2025 Commentary: Prostate Cancer
🚨 It’s here! The first instalment of our three-part ASCO Annual Meeting series is now LIVE.
🚨 It’s here! The first instalment of our three-part ASCO Annual Meeting series is now LIVE.
ASCO GU
ASCO GU
What was Neal Shore, MD, most looking forward to hearing at ASCO GU 2025?
What was Neal Shore, MD, most looking forward to hearing at ASCO GU 2025?
ASCO GU 2025 Social Media Report by LucidQuest
ASCO GU 2025 Social Media Report by LucidQuest
2025 Review and Renew Sedona: Updates in Genitourinary Cancer from ASCO GU - Dr Guru Sonpavde
2025 Review and Renew Sedona: Updates in Genitourinary Cancer from ASCO GU - Dr Guru Sonpavde
Research in Motion - ASCO GU 2025, Chromophobe RCC Poster Preview
Research in Motion - ASCO GU 2025, Chromophobe RCC Poster Preview
2023 - Les faits saillants de l'ASCO-GU
2023 - Les faits saillants de l'ASCO-GU
Genitourinary Cancer [2025] Update: ASCO GU 2025 Highlights with Nataliya Mar, MD MOASC
Genitourinary Cancer [2025] Update: ASCO GU 2025 Highlights with Nataliya Mar, MD MOASC